Skeletal muscle atrophy occurs in many chronic diseases and disuse conditions. Its severity
reduces patient recovery, independence and quality of life. The discovery of two muscle …

Muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx)/atrogin-1 were identified
more than 10 years ago as two muscle-specific E3 ubiquitin ligases that are increased …

Ubiquitin ligase Atrogin1/Muscle Atrophy F-box (MAFbx) up-regulation is required for
skeletal muscle atrophy but substrates and function during the atrophic process are poorly …

The ubiquitin–proteasome system (UPS) is the main regulatory mechanism of protein
degradation in skeletal muscle. The ubiquitin-ligase enzymes (E3s) have a central role in …

Skeletal muscle atrophy occurs in multiple clinical settings, including cancer, AIDS and
sepsis, and is caused in part by an increase in the rate of ATP-dependent ubiquitin …

In response to cancer, AIDS, sepsis and other systemic diseases inducing muscle atrophy,
the E3 ubiquitin ligase Atrogin1/MAFbx (MAFbx) is dramatically upregulated and this …

Atrophy of skeletal muscle is a serious consequence of numerous diseases, including
cancer and AIDS. Successful treatments for skeletal muscle atrophy could either block …

Skeletal muscle hypertrophy can be mediated by the induction of insulin-like growth factor-1
(IGF-1), which is a protein growth factor that is sufficient to induce skeletal muscle mass [10 …

Skeletal muscle hypertrophy is defined as an increase in muscle mass, which in the adult
animal comes as a result of an increase in the size, as opposed to the number, of pre …

Non‐Technical Summary Skeletal muscle has the capacity to modify its size in response to
external cues such as mechanical load, neural activity, hormones, stress and nutritional …